MAP2K7 and schwannoma: Consistent with PDGFR inhibition, we observed a dose-dependent decrease in AKT-Thr308 phosphorylation, a PI3K-dependent phosphorylation site, and a decrease in MEK/ERK phosphorylation, similar to those reported in sorafenib-treated schwannoma cells [10, 53, 54].